Cholera Vaccine Market Size, Growth & Trends 2034

Here’s a comprehensive market reference for the Cholera Vaccine Market, with citations and up-to-date insights:

2024: WHO granted prequalification to Euvichol‑S—an optimized version of Euvichol‑Plus—boosting global oral cholera vaccine supply from 38M to 50M doses .
Aug 2024: India’s Bharat Biotech announced Hillchol, an oral cholera vaccine with phase III success; facilities in Hyderabad (45 M doses/year, scalable to 200 M) were set up with a US‑$100M investment.
Feb 2025: Global stockpiles were depleted amid outbreaks (~805K cases in 2024); EuBiologics scaled from 40 M to 70 M doses and simplified its WHO‑approved vaccine .

Epidemic surges due to conflict & disasters—poor sanitation during crises increases vaccine demand .
Strong support from WHO, GAVI, PAHO — significant funding, stockpile efforts, and preventive campaigns .
Technology & capacity expansion — new formulations (Euvichol‑S, Hillchol), better manufacturing scaling, and phase III approvals .
Growth in preventive healthcare — increased emphasis on oral vaccines, particularly in developing regions .

Stockpile shortages during outbreaks—supply couldn’t match demand in 2024; limited manufacturers .
Logistical and distribution challenges—cold chain issues, underfunded healthcare, and misinformation hinder coverage .
High production & development costs—vaccine R&D and facility setup are capital-intensive .

Asia‑Pacific (~40% share): High endemicity (India, Bangladesh, Indonesia), strong government and WHO campaigns .
Africa/Middle East (~35%): Largest stockpile requests; repeated outbreaks demand robust vaccination .
North America (~20–37%): Leads funding, traveler/military vaccine use; Canada saw growth with single-dose Vaxchora .
Europe (~25%): Strong public health policies, manufacturer base, and traveler immunization .
Latin America (~15%): Growing through PAHO- and Canada-supported initiatives .

Oral vaccine dominance: Accounted for ~85% of market share (2023), with slow growth in injectable forms .
Single-dose strategies in emergencies: Interim WHO-approved single-dose use to meet urgent demand .
New players entering market: Bharat Biotech, EuBiologics, PaxVax (Emergent), Valneva, Sanofi expanding production .
Public–private partnerships: Focused on production capacity and vaccine campaigns .

Mass outbreak prevention: Emergency stockpile deployment in endemic or crisis regions .
Traveler and military immunizations: Single-dose Vaxchora and Dukoral remain key products .
Preventive public health campaigns: Routine drives in endemic zones, especially Asia-Pacific & Africa .

Demand volatility: Outbreak-driven patterns make manufacturing planning difficult .
Healthcare infrastructure gaps: Poor scenes in remote/conflict regions limit rollout .
Vaccine hesitancy and misinformation: Education barriers slow uptake in vulnerable areas .

Capacity expansion by new manufacturers: Hillchol and Euvichol‑S scale-up diversifies supply .
Single-dose oral vaccine uptake: Simplifies emergency campaigns, expedites herd immunity .
Emerging market growth: Endemic regions in Africa, Asia, and Latin America show increasing routine vaccination demand .
Public-private partnerships & funding: WHO, GAVI, PAHO investments foster expansion .

Enhanced production capacity & diversification—New entrants and scalable manufacturing aid stockpile resilience .
Global funding & organizational backing—WHO, GAVI, national initiatives ensure supply and deployment .
Easier oral & single-dose protocols—Improve emergency reach and reduce logistical burdens .
Emphasis on prevention & public health security—Growing priority in global health agendas .

Key players in this market include:

Leave a ReplyCancel Reply